CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to CLDX

CDX-1401 in combination with Resiquimod and/or Poly-ICLC

Phase 2
Celldex Therapeutics, Inc. (CLDX)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Advanced Malignancies

View Full Landscape
Drug Information

Target Indication

Advanced Malignancies

Clinical Trial

NCT00948961

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.